The Australian Competition and Consumer Commission is speaking out against proposed changes to the nation’s competition laws, claiming the reforms will significantly weaken regulators’ ability to fight cartels.
Reports say the Harper competition review, which released its first draft of proposed changes in September, has earned significant backlash from the ACCC. In its most recent criticism, the regulator says it has “serious reservations” about changes to the cartel prohibitions.
”While the ACCC supports simplification, any amendments should not fundamentally alter the existing scope of the prohibitions,” the ACCC said in a submission.
According to reports, the review panel wants to narrow the definition of “competition” to allow exemptions for companies whose main operations are overseas. Current law applies to any two companies operating within Australia that are in competition with each other.
But the ACCC says such a move could be detrimental to cartel enforcement. “The ACCC considers the cartel provisions should not be amended to be limited to markets in Australia,” the regulator said. “it would risk substantively undermining the efficacy of the cartel provisions.”
The panel is slated to present its final report in March, reports say.
Full content: Sydney Morning Herald
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas